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Endovascular repair is a valid alternative for patients with abdominal aortic aneurysms. However, in patients with
concomitant aortocaval ﬁstulas, type II endoleaks may result in a persistent communication between the aneurysm sac and
the inferior vena cava. In these patients, prompt closure of the persistent ﬁstula has been advocated. We present a patient
with an abdominal aortic aneurysm, with aortocaval ﬁstula, who was managed endovascularly. Aneurysm sac shrinkage
was observed despite persistent aortocaval communication due to type II endoleak. This case demonstrates that
conservative management of type II endoleaks associated with persistent aortocaval ﬁstulas is possible and may result in
favorable aneurysm sac remodelling. (J Vasc Surg 2013;58:1080-3.)Endovascular aneurysm repair (EVAR) is a valid alter-
native over open reconstruction in patients with (ruptured)
abdominal aortic aneurysms (AAAs).1 However, in patients
with concomitant arteriovenous (AV) ﬁstulas, type II
endoleaks may result in a persistent communication
between the aneurysm sac and the venous system. In the
current literature, early closure of the ﬁstula has been advo-
cated due to concerns about future aneurysm-related
complications.2,3 We present an AAA patient with an aor-
tocaval ﬁstula who was managed conservatively and in
whom favorable aneurysm sac remodelling was observed,
despite a persistent aortocaval communication due to
a large type II endoleak.CASE REPORT
A 61-year-old man presented at the emergency department
with acute low back and abdominal pain. The patient had a history
of hypertension and chronic obstructive pulmonary disease.
Prescription medications included a b-blocker, an angiotensin II
inhibitor, and a short-acting b2-adrenergic receptor agonist. On
admission, his heart rate and blood pressure were within normal
reference ranges (72 beats/min and 123/87 mm Hg, respec-
tively). Physical examination revealed a tender, pulsatile abdominaltheDepartmentofVascular Surgery,ErasmusUniversityMedicalCenter,
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0mass, without abdominal bruit or thrill. No clinical signs of venous
hypertension or heart failure were observed. Laboratory results
showed no hepatic or kidney dysfunction. A computed tomog-
raphy angiography (CTA) demonstrated a large AAA (10 cm in
transverse diameter) with an associated aortocaval ﬁstula (Fig 1).
The patient’s anatomy was suitable for EVAR, and a bifurcated
Endurant endovascular device (Medtronic Inc, Minneapolis,
Minn) was used for exclusion. The perioperative ﬁnal angiography
showed an evident type II endoleak from the inferior mesenteric
artery, but no further action was taken.
The patient had an uneventful postoperative recovery and was
discharged after 5 days. In addition, postoperative renal and
hepatic function remained normal.
A postoperative CTA showed persistent communication with
the inferior vena cava (IVC) as a result of the type II endoleak
(Fig 1). To evaluate the systemic repercussion of the persistent
aortocaval ﬁstula, the patient was referred for a formal cardiac
evaluation after 3 months. He was asymptomatic, and results of
electrocardiography were normal. Echocardiography showed
a normal systolic left ventricular ejection fraction, with no signs
of increased right atrial ﬁlling pressure and a physiologic collapse
of the IVC. Consequently, no further action was taken. After 1
year of follow-up, CTA showed shrinkage of the aneurysm sac
diameter by 10 mm and an 8% reduction in volume compared
with the postoperative CTA,4 despite the persistent type II endo-
leak (Fig 2).
DISCUSSION
Persistent AV ﬁstulas after EVAR have been reported,
but the natural history of this complication remains
unknown; moreover, there is no clear evidence in the
current literature supporting treatment over observation.
Our case demonstrates that persistent aortocaval communi-
cation due to type II endoleak is possible and that a conser-
vative approach may be preferable in the absence of
systemic manifestations and in the face of favorable aneu-
rysm sac remodelling.
Aortocaval ﬁstulas are, by deﬁnition, high-ﬂow ﬁstulas
that may result in complications due to increased cardiac
Fig 1. A preoperative (A) luminal three-dimensional reconstruction and a (B) coronal view of the computed
tomography angiography (CTA) show a 10-cm large abdominal aortic aneurysm (AAA) with associated aortocaval
ﬁstula (ACF, white arrowheads). A postoperative (C) reconstruction and a (D) coronal view show the persistent
aortocaval ﬁstula at the 1-year follow-up. *Artery of Drummond; IMA, inferior mesenteric artery; IVC, inferior vena
cava; SMA, superior mesenteric artery.
Fig 2. Postoperative computed tomography angiography (CTA) at (A) 6 weeks and at the (B) 1-year follow-up shows
a 10-mm decrease in diameter. Notice the large type II endoleak associated with a persistent aortocaval ﬁstula
(white arrowheads).
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advised. Patients with aortocaval ﬁstulas have traditionally
been treated with open repair, with mortality rates rangingfrom 16% to 66%.5 Because EVAR has been adopted as
valid treatment for (ruptured) AAAs,1 also in the presence
of aortocaval ﬁstulas, persistent communication between
Fig 3. Different dynamics are shown in the aneurysm sac between a type II endoleak (left) without and (right) with an
arteriovenous (AV) ﬁstula. IVC, Inferior vena cava.
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endoleak. The question remains ifdand howdwe should
manage these persistent ﬁstulas.
Type II endoleak is deﬁned as persistent retrograde
ﬂow into the aneurysm sac from the inferior mesenteric,
lumbar, or other arteries, without attachment-site leak.8
They are classiﬁed as (a) simple, with one patent branch
or (b) complex, with two or more patent branches.9 These
endoleaks are considered important because they may
result in repressurization of the excluded aneurysm sac,
with consequent growth and, ultimately, rupture. How-
ever, in the presence of persistent caval communication,
type II endoleaks are subject to different ﬂow and pressure
dynamics caused by the connection with the low-pressure
venous system (2-8 mm Hg).10 The connection causes
a pressure gradient, resulting in a decrease of in-sac pres-
sure (Fig 3), mimicking the concept of aneurysm sac fenes-
tration.11 Owing to the low-pressure nature, this special
type of type II endoleak has a very low probability of aneu-
rysm sac growth. This was conﬁrmed in our patient, in
whom we observed signiﬁcant aneurysm sac shrinkage at
1 year (Fig 2).
Several cases of endovascular treatment for AAA
patients with aortocaval ﬁstulas have been described.12-15
However, only four case reports of persistent aortocaval
ﬁstulas have been published to date. Burke et al2 reported
a patient with a type II endoleak 4 days postoperatively,
which was immediately treated with a cuff in the IVC
and glue in the aneurysm sac. Kopp et al3 reported a similar
patient who underwent secondary coiling of a persistent
type II endoleak. Lastly, Vetrhus et al15 suggested that
persistent ﬁstulas in this context tend to resolve spontane-
ously, which did not occur in our patient. The ﬁstulas intheir two patients resolved on-table in one patient and after
4 weeks in the other, without further intervention.15 Taken
together, the chance of a persistent aortocaval ﬁstula after
EVAR is rather small but is considerable due to the high
frequency of type II endoleaks after EVAR.
We treated our patient conservatively because no
systemic repercussions of the AV ﬁstula were present and
secondary interventions for type II endoleaks are generally
reserved for persistent endoleaks ($6 months) associated
with aneurysm sac enlargement.16 However, we acknowl-
edge that conservative management in our patient might
result in complications. Increased cardiac output and, ulti-
mately, heart failure may develop from AV ﬁstulas. Never-
theless, we considered this risk was relatively small because
the arterial component of the ﬁstula in our patient resulted
from retrograde ﬂow from the inferior mesenteric artery.
Moreover, a physiologic collapse of the IVC was observed,
emphasizing the low-pressure nature of the ﬁstula. None-
theless, careful and continued cardiac evaluation is required
to ensure early identiﬁcation of this possible complication.
In addition, embolization may occur as a result of
dislodgment of aneurysm sac debris; however, we believe
that the risk for clinically signiﬁcant embolization is
minute. First, the chance of embolization from untreated
AAAs is very small.17 Second, closing an AV ﬁstula with
an implant may also induce thromboembolism. Lastly,
the chance of embolization due to manipulation during
secondary intervention to close the AV ﬁstula is probably
higher than the embolization risk itself.
Because compression of the IVC was observed, throm-
bosis could occur. Therefore, implantation of an endograft
in the IVC could be considered to exclude the AV ﬁstula
and treat IVC compression. However, this compression is
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bosis is anecdotic. Also, stent graft placement in a signiﬁ-
cantly compressed IVC may yield a suboptimal result,
with a risk of endograft collapse or acute stent thrombosis,
or both.
CONCLUSIONS
Our case shows that in the absence of systemic reper-
cussions, persistent aortocaval ﬁstulas due to type II endo-
leak after EVAR may be managed conservatively and that
favorable remodeling of the aneurysm sac is possible.
Nevertheless, close observation, including periodic cardiac
evaluation, is mandatory. Secondary intervention may be
reserved for patients with persistent aortocaval ﬁstulas
combined with aneurysm sac enlargement or systemic
manifestations.
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